Key result
GPT-4 outperforms GPT-3.5 by providing comprehensive responses to ~95% of general amyloidosis questions.
Why the study?
Patients with rare diseases like amyloidosis are at risk for low health literacy, and large language models like ChatGPT may improve access to accurate, plain-language education materials.
Does ChatGPT provide accurate and reproducible answers to amyloidosis-related questions?
Does ChatGPT provide accurate and reproducible answers to amyloidosis-related questions?
ChatGPT, particularly GPT-4, provides highly accurate and reproducible answers to amyloidosis-related questions, suggesting its potential as a supplemental tool for patient education in rare diseases.
Answers are grounded in this paper and cite their sources.
May support GPT-4 for amyloidosis education; leaves open clinical integration, safety, and outcome impact.
Amyloidosis is a rare, multisystem disease with several subtypes including AA (secondary), AL (amyloid light chain), and ATTR (transthyretin amyloidosis). In addition to variable symptoms and multidisciplinary management, amyloidosis being a rare disease further contributes to patients being at risk for decreased health literacy regarding their condition. Increased access to education materials containing simple, plain language may bridge literacy gaps and improve outcomes for patients with rare diseases such as amyloidosis. The large language model (LLM), Chat Generative Pre-Trained Transformer (ChatGPT), may be a powerful tool for improving the availability of accurate and easy to understand education materials. Amyloidosis-related questions from cardiology, gastroenterology, and neurology were sourced from esteemed medical societies and institutions along with amyloidosis Facebook support groups and inputted into ChatGPT-3.5 and GPT-4. Answers were graded on 4-point scale with both models responding to the majority of questions with either “comprehensive” or “correct but inadequate” answers with only 1 (1.2%) answer by GPT-3.5 graded as “completely inaccurate”. When assessing reproducibility, GPT-3.5 scored reliably on more than 83.3% of responses, while GPT-4 produced above 98.2% consistent answers. Our findings show that ChatGPT can potentially serve as a supplemental tool in disseminating vital health education to patients living with amyloidosis.
No takes yet. Share an insight, caveat, or question.
King et al. (2023) studied Amyloidosis (n=98). GPT-4 vs. GPT-3.5 was evaluated on Comprehensive responses (Grade 1) for general amyloidosis questions. GPT-4 provided comprehensive responses to 94.6% of general amyloidosis questions compared to 85.7% for GPT-3.5, demonstrating its potential as a supplemental tool for patient health education.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: